Baseline polysaccharide-specific antibodies may not consistently inhibit booster antibody responses in infants to a serogroup C meningococcal protein-polysaccharide conjugate vaccine

Vaccine

Volumn 30, Issue 28, 2012, Pages 4153-4159

  Blanchard Rohner, Geraldine ^a,b   Watt, Hilary ^c   Kelly, Dominic F ^a   Yu, Ly Mee ^c   Snape, Matthew D ^a   Pollard, Andrew J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Baseline antibody; MenC; Protein polysaccharide conjugate vaccine; Response to booster

Indexed keywords

9 VALENT PNEUMOCOCCAL MENINGOCOCCAL GROUP C CONJUGATE VACCINE; ANTIBODY; DIPHTHERIA TOXOID CRM197; HAEMOPHILUS INFLUENZAE TYPE B NEISSERIA MENINGITIDIS C TETANUS TOXOID CONJUGATE VACCINE; IMMUNOGLOBULIN G; MENINGOCOCCAL A AND C POLYSACCHARIDE VACCINE; MENINGOCOCCAL C POLYSACCHARIDE CONJUGATE VACCINE; MENINGOCOCCUS VACCINE; PNEUMOCOCCUS VACCINE; POLYSACCHARIDE VACCINE; TETANUS TOXOID; UNCLASSIFIED DRUG;

ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; BLOMQVIST METHOD; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; HUMAN; IMMUNIZATION; INFANT; MATHEMATICAL MODEL; MEASUREMENT ERROR; OLDHAM METHOD; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

ANIMALS; ANTIBODIES, BACTERIAL; HUMANS; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN G; INFANT; MENINGOCOCCAL VACCINES; MODELS, STATISTICAL; NEISSERIA MENINGITIDIS, SEROGROUP C; VACCINES, CONJUGATE;

EID: 84861708231     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.04.063     Document Type: Article

References (34)

1. Heyman B. Regulation of antibody responses via antibodies, complement, and Fc receptors. Annual Review of Immunology 2000, 18:709-737.
2. Heyman B. Feedback regulation by IgG antibodies. Immunology Letters 2003, 88(2):157-161. (August 5).
3. Hjelm F., Carlsson F., Getahun A., Heyman B. Antibody-mediated regulation of the immune response. Scandinavian Journal of Immunology 2006, 64(September (3)):177-184.
4. Siegrist C.A. Mechanisms by which maternal antibodies influence infant vaccine responses: review of hypotheses and definition of main determinants. Vaccine 2003, 21(24):3406-3412. (July 28).
5. Siegrist C.A., Barrios C., Martinez X., Brandt C., Berney M., Cordova M., et al. Influence of maternal antibodies on vaccine responses: inhibition of antibody but not T cell responses allows successful early prime-boost strategies in mice. European Journal of Immunology 1998, 28(December (12)):4138-4148.
6. Danilova E., Shiryayev A., Kristoffersen E.K., Sjursen H. Attenuated immune response to tetanus toxoid in young healthy men protected against tetanus. Vaccine 2005, 23(42):4980-4983. (October 10).
7. Danilova E., Shiryayev A., Skogen V., Kristoffersen E.K., Sjursen H. Short-term booster effect of diphtheria toxoid in initially long-term protected individuals. Vaccine 2005, 23(12):1446-1450. (February 10).
8. Ronne T., Valentelis R., Tarum S., Griskevica A., Wachmann C.H., Aggerbeck H., et al. Immune response to diphtheria booster vaccine in the Baltic states. The Journal of Infectious Diseases 2000, 181(February (Suppl. 1)):S213-S219.
9. Nicolay U., Girgsdies O.E., Banzhoff A., Hundt E., Jilg W. Diphtheria booster vaccination: one or two injections?. Vaccine 1999, 17(18):2223-2228. (May 4).
10. Blanchard Rohner G., Snape M.D., Kelly D.F., John T., Morant A., Yu L.M., et al. The magnitude of the antibody and memory B cell responses during priming with a protein-polysaccharide conjugate vaccine in human infants is associated with the persistence of antibody and the intensity of booster response. The Journal of Immunology 2008, 180(4):2165-2173. (Feb 15).
11. Hayes R.J. Methods for assessing whether change depends on initial value. Statistics in Medicine 1988, 7(September (9)):915-927.
12. Tu Y.K., Gilthorpe M.S. Revisiting the relation between change and initial value: a review and evaluation. Statistics in Medicine 2007, 26(2):443-457. (January 30).
13. Oldham P.D. A note on the analysis of repeated measurements of the same subjects. Journal of Chronic Diseases 1962, October (15):969-977.
14. Buttery J.P., Riddell A., McVernon J., Chantler T., Lane L., Bowen-Morris J., et al. Immunogenicity and safety of a combination pneumococcal-meningococcal vaccine in infants: a randomized controlled trial. Journal of the American Medical Association 2005, 293(14):1751-1758. (April 13).
15. Riddell A., Buttery J.P., McVernon J., Chantler T., Lane L., Bowen-Morris J., et al. A randomized study comparing the safety and immunogenicity of a conjugate vaccine combination containing meningococcal group C and pneumococcal capsular polysaccharide-CRM197 with a meningococcal group C conjugate vaccine in healthy infants: challenge phase. Vaccine 2007, 25(19):3906-3912. (May 10).
16. MacLennan J.M., Shackley F., Heath P.T., Deeks J.J., Flamank C., Herbert M., et al. Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants: a randomized controlled trial. Journal of the American Medical Association 2000, 283(21):2795-2801. (June 7).
17. English M., MacLennan J.M., Bowen-Morris J.M., Deeks J., Boardman M., Brown K., et al. A randomised, double-blind, controlled trial of the immunogenicity and tolerability of a meningococcal group C conjugate vaccine in young British infants. Vaccine 2000, 19(9-10):1232-1238. (December 8).
18. Snape M.D., Maclennan J.M., Lockhart S., English M., Yu L.M., Moxon R.E., et al. Demonstration of immunologic memory using serogroup C meningococcal glycoconjugate vaccine. The Pediatric Infectious Disease Journal 2009, 28(February (2)):92-97.
19. Pace D., Snape M., Westcar S., Oluwalana C., Yu L.M., Begg N., et al. A novel combined Hib-MenC-TT glycoconjugate vaccine as a booster dose for toddlers: a phase 3 open randomised controlled trial. Archives of Disease in Childhood 2008, 93(November (11)):963-970.
20. Pace D., Snape M., Westcar S., Hamaluba M., Yu L.M., Begg N., et al. A new combination haemophilus influenzae type B and Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine for primary immunization of infants. The Pediatric Infectious Disease Journal 2007, 26(November (11)):1057-1059.
21. Blance A., Tu Y.K., Gilthorpe M.S. A multilevel modelling solution to mathematical coupling. Statistical Methods in Medical Research 2005, 14(December (6)):553-565.
22. Peltola H. Meningococcal vaccines: current status and future possibilities. Drugs 1998, 55(March (3)):347-366.
23. Gold R., Lepow M.L., Goldschneider I., Draper T.F., Gotshlich E.C. Kinetics of antibody production to group A and group C meningococcal polysaccharide vaccines administered during the first six years of life: prospects for routine immunization of infants and children. The Journal of Infectious Diseases 1979, 140(November (5)):690-697.
24. Tu Y.K., Maddick I.H., Griffiths G.S., Gilthorpe M.S. Mathematical coupling can undermine the statistical assessment of clinical research: illustration from the treatment of guided tissue regeneration. Journal of Dentistry 2004, 32(February (2)):133-142.
25. Tu Y.K., Gilthorpe M.S., Griffiths G.S. Is reduction of pocket probing depth correlated with the baseline value or is it mathematical coupling?. Journal of Dental Research 2002, 81(October (10)):722-726.
26. Gheesling L.L., Carlone G.M., Pais L.B., Holder P.F., Maslanka S.E., Plikaytis B.D., et al. Multicenter comparison of Neisseria meningitidis serogroup C anti-capsular polysaccharide antibody levels measured by a standardized enzyme-linked immunosorbent assay. Journal of Clinical Microbiology 1994, 32(June (6)):1475-1482.
27. Elie C.M., Holder P.K., Romero-Steiner S., Carlone G.M. Assignment of additional anticapsular antibody concentrations to the Neisseria meningitidis group A, C, Y, and W-135 meningococcal standard reference serum CDC1992. Clinical and Diagnostic Laboratory Immunology 2002, 9(May (3)):725-726.
28. Granoff D.M., Maslanka S.E., Carlone G.M., Plikaytis B.D., Santos G.F., Mokatrin A., et al. A modified enzyme-linked immunosorbent assay for measurement of antibody responses to meningococcal C polysaccharide that correlate with bactericidal responses. Clinical and Diagnostic Laboratory Immunology 1998, 5(July (4)):479-485.
29. Dagan R., Eskola J., Leclerc C., Leroy O. Reduced response to multiple vaccines sharing common protein epitopes that are administered simultaneously to infants. Infection and Immunity 1998, 66(May (5)):2093-2098.
30. Dagan R., Poolman J., Siegrist C.A. Glycoconjugate vaccines and immune interference: a review. Vaccine 2010, 28(34):5513-5523.
31. Barington T., Skettrup M., Juul L., Heilmann C. Non-epitope-specific suppression of the antibody response to Haemophilus influenzae type b conjugate vaccines by preimmunization with vaccine components. Infection and Immunity 1993, 61(February (2)):432-438.
32. Insel R.A. Potential alterations in immunogenicity by combining or simultaneously administering vaccine components. Annals of the New York Academy of Sciences 1995, 754:35-47. (May 31).
33. Barington T., Kristensen K., Henrichsen J., Heilmann C. Influence of prevaccination immunity on the human B-lymphocyte response to a Haemophilus influenzae type b conjugate vaccine. Infection and Immunity 1991, 59(March (3)):1057-1064.
34. Daum R.S., Zenko C.E., Given G.Z., Ballanco G.A., Parikh H., Germino K. Magnitude of interference after diphtheria-tetanus toxoids-acellular pertussis/Haemophilus influenzae type b capsular polysaccharide-tetanus vaccination is related to the number of doses administered. The Journal of Infectious Diseases 2001, 184(10):1293-1299. (November 15).